Brisbane, Australia, 28 November 2019 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, and Coviu, Australia’s leading telehealth software platform, have entered into a non-binding memorandum of understanding (MOU) to integrate ResApp’s acute respiratory diagnostic test, ResAppDx-EU into Coviu’s browser-based telehealth platform.
The integration will see ResAppDx-EU become available to the 5,500+ clinicians who currently use the Coviu platform. Clinicians will then have the ability to accurately diagnose respiratory disease in a telehealth setting.
Most people will develop an acute respiratory tract infection every year, and up to a half of all telehealth consultations are respiratory-related. Standard diagnostic aids such as stethoscopes are unavailable during a video-based telehealth consultation.
A spinout from CSIRO’s Data61, Coviu’s telehealth platform makes it easy for healthcare providers to offer their services directly to patients via video consultation and powers the Australian government-funded healthdirect Video Call. Coviu hosts video consultations for over 5,500 clinicians and over 1,000 individual clinics, offering the potential to reach millions of Australians.
ResAppDx-EU is a software application used by clinicians to diagnose the most common respiratory diseases. The software uses machine learning algorithms that analyse a patient’s cough sounds to diagnose disease. ResAppDx-EU is CE Marked in the European Union and Therapeutics Good Administration (TGA) approved in Australia.
“We are excited to be working with Coviu, which has developed a technologically-advanced telehealth platform with one of the largest active deployments in Australia,” said Tony Keating, CEO and Managing Director of ResApp. “This is a great opportunity to integrate ResApp’s solution into a leading telehealth provider’s platform and demonstrate the value we deliver in the telehealth setting.”
Dr Silvia Pfeiffer, CEO and co-founder of Coviu added, “At Coviu we are committed to providing the best software for video visits so that doctors can bring the same level of outstanding care that they provide in face-to-face consultations to online consultations. We look forward to being able to provide ResApp’s respiratory diagnostic solutions as a tool for clinicians who use our platform to accurately diagnose and care for patients with respiratory conditions.”
Coviu and ResApp will work together under a joint development agreement for the next four months to integrate ResAppDx-EU into Coviu’s browser-based telehealth platform, to devise a workflow for directing patients and clinicians towards the use of ResAppDx-EU in appropriate circumstances and to prepare a list of actions for clinicians to take after reviewing the test results. Before the conclusion of the project, ResApp and Coviu will enter into negotiations on the cost model of using ResAppDx-EU on the Coviu platform within Australia.
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis, croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp’s smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit www.resapphealth.com.au
About Coviu Global Pty Ltd
Coviu Global Pty Ltd is an emerging startup out of CSIRO’s Data61, offering a video consultation software to healthcare businesses. It brings the specific workflows and tools necessary for healthcare into an online video call while satisfying regulatory requirements around security and privacy. For more information, please visit www.coviu.com.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.